Aberration of p53 and DCC in gastric and colorectal cancer

Masafumi Kataoka, Takahiro Okabayashi, Hiroki Johira, Shin Nakatani, Akira Nakashima, Akira Takeda, Masahiko Nishizaki, Kunzo Orita, Noriaki Tanaka

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

We investigated the expression of p53 protein by immunohistochemistry and the expression of deleted in colorectal carcinoma (DCC) mRNA by the reverse transcription-polymerase chain reaction (RT-PCR) method in surgically resected tumors of gastric and colorectal cancers and compared these results to the clinicopathological features. Positive immunoreactions of p53 were observed in 21 of 42 gastric cancers (50%) and 25 of 37 colorectal cancers (67.6%). Decreased expression of DCC mRNA was observed in 15 of 38 gastric cancers (39.5%) and 10 of 28 colorectal cancers (35.7%). There was a significant correlation between the immunoreaction of p53 and the depth of tumor invasion in gastric cancer, as well as between the decreased expression of DCC mRNA and nodal metastasis in colorectal cancer. In early cases without metastasis and invasion beyond muscularis propria, none of six gastric cancers showed a p53 immunoreaction, while seven of 9 colorectal cancers showed positive immunoreactions. On the other hand, two of 4 gastric cancers showed decreased expression of DCC mRNA; whereas, none of the seven colorectal cancers did. Alteration of p53 might occur at a later stage in gastric cancer than in colorectal cancer and be associated with the acquisition of an invasive character. In contrast to gastric cancer, decreased expression of DCC mRNA might be present in a later stage in colorectal cancer than in gastric cancer, and be related to the acquisition of metastatic character to the lymph nodes. In conclusion, alterations of p53 or DCC may play different roles in the progression of gastric cancers as compared to colorectal cancers, and the occurrence of both p53 and DCC genes mutations may cause these cancers to become more malignant.

Original languageEnglish
Pages (from-to)99-103
Number of pages5
JournalOncology Reports
Volume7
Issue number1
Publication statusPublished - 2000

Fingerprint

Stomach Neoplasms
Colorectal Neoplasms
Messenger RNA
Neoplasm Metastasis
Neoplasms
Reverse Transcription
Lymph Nodes
Immunohistochemistry

Keywords

  • Colorectal cancer
  • Deleted in colorectal carcinoma gene
  • Gastric cancer
  • p53

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kataoka, M., Okabayashi, T., Johira, H., Nakatani, S., Nakashima, A., Takeda, A., ... Tanaka, N. (2000). Aberration of p53 and DCC in gastric and colorectal cancer. Oncology Reports, 7(1), 99-103.

Aberration of p53 and DCC in gastric and colorectal cancer. / Kataoka, Masafumi; Okabayashi, Takahiro; Johira, Hiroki; Nakatani, Shin; Nakashima, Akira; Takeda, Akira; Nishizaki, Masahiko; Orita, Kunzo; Tanaka, Noriaki.

In: Oncology Reports, Vol. 7, No. 1, 2000, p. 99-103.

Research output: Contribution to journalArticle

Kataoka, M, Okabayashi, T, Johira, H, Nakatani, S, Nakashima, A, Takeda, A, Nishizaki, M, Orita, K & Tanaka, N 2000, 'Aberration of p53 and DCC in gastric and colorectal cancer', Oncology Reports, vol. 7, no. 1, pp. 99-103.
Kataoka M, Okabayashi T, Johira H, Nakatani S, Nakashima A, Takeda A et al. Aberration of p53 and DCC in gastric and colorectal cancer. Oncology Reports. 2000;7(1):99-103.
Kataoka, Masafumi ; Okabayashi, Takahiro ; Johira, Hiroki ; Nakatani, Shin ; Nakashima, Akira ; Takeda, Akira ; Nishizaki, Masahiko ; Orita, Kunzo ; Tanaka, Noriaki. / Aberration of p53 and DCC in gastric and colorectal cancer. In: Oncology Reports. 2000 ; Vol. 7, No. 1. pp. 99-103.
@article{37da702e2b2e48659308a0ba584dbe48,
title = "Aberration of p53 and DCC in gastric and colorectal cancer",
abstract = "We investigated the expression of p53 protein by immunohistochemistry and the expression of deleted in colorectal carcinoma (DCC) mRNA by the reverse transcription-polymerase chain reaction (RT-PCR) method in surgically resected tumors of gastric and colorectal cancers and compared these results to the clinicopathological features. Positive immunoreactions of p53 were observed in 21 of 42 gastric cancers (50{\%}) and 25 of 37 colorectal cancers (67.6{\%}). Decreased expression of DCC mRNA was observed in 15 of 38 gastric cancers (39.5{\%}) and 10 of 28 colorectal cancers (35.7{\%}). There was a significant correlation between the immunoreaction of p53 and the depth of tumor invasion in gastric cancer, as well as between the decreased expression of DCC mRNA and nodal metastasis in colorectal cancer. In early cases without metastasis and invasion beyond muscularis propria, none of six gastric cancers showed a p53 immunoreaction, while seven of 9 colorectal cancers showed positive immunoreactions. On the other hand, two of 4 gastric cancers showed decreased expression of DCC mRNA; whereas, none of the seven colorectal cancers did. Alteration of p53 might occur at a later stage in gastric cancer than in colorectal cancer and be associated with the acquisition of an invasive character. In contrast to gastric cancer, decreased expression of DCC mRNA might be present in a later stage in colorectal cancer than in gastric cancer, and be related to the acquisition of metastatic character to the lymph nodes. In conclusion, alterations of p53 or DCC may play different roles in the progression of gastric cancers as compared to colorectal cancers, and the occurrence of both p53 and DCC genes mutations may cause these cancers to become more malignant.",
keywords = "Colorectal cancer, Deleted in colorectal carcinoma gene, Gastric cancer, p53",
author = "Masafumi Kataoka and Takahiro Okabayashi and Hiroki Johira and Shin Nakatani and Akira Nakashima and Akira Takeda and Masahiko Nishizaki and Kunzo Orita and Noriaki Tanaka",
year = "2000",
language = "English",
volume = "7",
pages = "99--103",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Aberration of p53 and DCC in gastric and colorectal cancer

AU - Kataoka, Masafumi

AU - Okabayashi, Takahiro

AU - Johira, Hiroki

AU - Nakatani, Shin

AU - Nakashima, Akira

AU - Takeda, Akira

AU - Nishizaki, Masahiko

AU - Orita, Kunzo

AU - Tanaka, Noriaki

PY - 2000

Y1 - 2000

N2 - We investigated the expression of p53 protein by immunohistochemistry and the expression of deleted in colorectal carcinoma (DCC) mRNA by the reverse transcription-polymerase chain reaction (RT-PCR) method in surgically resected tumors of gastric and colorectal cancers and compared these results to the clinicopathological features. Positive immunoreactions of p53 were observed in 21 of 42 gastric cancers (50%) and 25 of 37 colorectal cancers (67.6%). Decreased expression of DCC mRNA was observed in 15 of 38 gastric cancers (39.5%) and 10 of 28 colorectal cancers (35.7%). There was a significant correlation between the immunoreaction of p53 and the depth of tumor invasion in gastric cancer, as well as between the decreased expression of DCC mRNA and nodal metastasis in colorectal cancer. In early cases without metastasis and invasion beyond muscularis propria, none of six gastric cancers showed a p53 immunoreaction, while seven of 9 colorectal cancers showed positive immunoreactions. On the other hand, two of 4 gastric cancers showed decreased expression of DCC mRNA; whereas, none of the seven colorectal cancers did. Alteration of p53 might occur at a later stage in gastric cancer than in colorectal cancer and be associated with the acquisition of an invasive character. In contrast to gastric cancer, decreased expression of DCC mRNA might be present in a later stage in colorectal cancer than in gastric cancer, and be related to the acquisition of metastatic character to the lymph nodes. In conclusion, alterations of p53 or DCC may play different roles in the progression of gastric cancers as compared to colorectal cancers, and the occurrence of both p53 and DCC genes mutations may cause these cancers to become more malignant.

AB - We investigated the expression of p53 protein by immunohistochemistry and the expression of deleted in colorectal carcinoma (DCC) mRNA by the reverse transcription-polymerase chain reaction (RT-PCR) method in surgically resected tumors of gastric and colorectal cancers and compared these results to the clinicopathological features. Positive immunoreactions of p53 were observed in 21 of 42 gastric cancers (50%) and 25 of 37 colorectal cancers (67.6%). Decreased expression of DCC mRNA was observed in 15 of 38 gastric cancers (39.5%) and 10 of 28 colorectal cancers (35.7%). There was a significant correlation between the immunoreaction of p53 and the depth of tumor invasion in gastric cancer, as well as between the decreased expression of DCC mRNA and nodal metastasis in colorectal cancer. In early cases without metastasis and invasion beyond muscularis propria, none of six gastric cancers showed a p53 immunoreaction, while seven of 9 colorectal cancers showed positive immunoreactions. On the other hand, two of 4 gastric cancers showed decreased expression of DCC mRNA; whereas, none of the seven colorectal cancers did. Alteration of p53 might occur at a later stage in gastric cancer than in colorectal cancer and be associated with the acquisition of an invasive character. In contrast to gastric cancer, decreased expression of DCC mRNA might be present in a later stage in colorectal cancer than in gastric cancer, and be related to the acquisition of metastatic character to the lymph nodes. In conclusion, alterations of p53 or DCC may play different roles in the progression of gastric cancers as compared to colorectal cancers, and the occurrence of both p53 and DCC genes mutations may cause these cancers to become more malignant.

KW - Colorectal cancer

KW - Deleted in colorectal carcinoma gene

KW - Gastric cancer

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=0033630041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033630041&partnerID=8YFLogxK

M3 - Article

C2 - 10601600

AN - SCOPUS:0033630041

VL - 7

SP - 99

EP - 103

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1

ER -